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1. Introduction 
Control of energy metabolism is crucial for optimal functioning of organs and tissues. 
Amongst all nutrients, glucose is the principal energy source for most cells and, therefore, 
minimum blood glucose levels must be guaranteed. Alterations in glycaemia can lead to 
hyperglycaemic states (producing protein glycosylation and toxicity in glucose-sensitive 
cells) or hypoglycaemic states (that can affect brain function), both harmful. Therefore, 
mechanisms must exist to keep glycaemia in a narrow physiological range (4-8 mM) 
independently of the nutritional state. To achieve control of blood glucose levels, our body 
has a complex, interorgan signaling system using nutrients (glucose, lipids, amino acids), 
hormones (insulin, glucagon, ghrelin, etc.) and the autonomic nervous system. In response 
to these signals, organs and tissues (mainly intestine, endocrine pancreas, liver, skeletal 
muscle, adipose tissue, brain and adrenal glands) adapt their function to energetic 
requirements. 
The liver plays a pivotal role in the maintenance of glucose homeostasis by continuously 
adapting its metabolism to energetic needs. In the fed state, when blood glucose levels are 
high and there is insulin, liver takes-up part glucose to replenish glycogen stores. Besides, 
when glucose stores are full, the liver has the capacity to synthesize lipids de novo from 
glucose for-long term energy storage. Lipids are packaged in very low-density lipoprotein 
(VLDL) particles and then transported to the adipose tissue. Conversely during starvation, 
when glycaemia falls and glucagon increases, the liver produces glucose to maintain 
circulating glucose levels by breaking down glycogen stores or by synthesizing glucose de 
novo through gluconeogenesis. Gluconeogenesis, as an energy-consuming pathway, is 
linked to ǃ-oxidation of fatty acids (fuel supplier pathway). 
From this introduction on the regulation of glucose homeostasis, one can appreciate the 
close relation that exists between carbohydrate metabolism and lipid metabolism in the 
liver. Therefore, alterations in hepatic carbohydrate metabolic pathways may directly 
affect hepatic and/or blood lipid levels. Particularly, this chapter will focus on evaluating 
the incidence of glucokinase (GK) –the first enzyme of the glycolytic pathway in the liver- 
on lipidemia and on hepatic lipid content. But first, an introductory overview of the 
physiology behind the first-pass metabolism of dietary glucose in the liver will be 
presented. 
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2. Liver glucose metabolism 
After a meal rich in carbohydrates, high levels of glucose reach the liver via portal vein. 
Glucose enters passively the hepatocyte through GLUT-2, a facilitated glucose transporter, 
and then is rapidly phosphorylated by GK at the sixth carbon to obtain glucose-6-phosphate 
which cannot escape the cell. From a functional perspective, it is important to recognize that 
both GLUT2 and glucokinase are expressed in cell types in which glucose metabolism has to 
vary accordingly to extracellular glucose concentration (glucose sensors). The high Km for 
glucose of both proteins, and the absence of product inhibition by glucose-6-phosphate, 
ensure that glucose uptake and phosphorylation in these cells are proportional to 
extracellular glucose concentration throughout the physiological range of glycaemia 
The product of GK reaction, glucose-6-phosphate, is the gateway to the major pathways of 
glucose utilization: glycogen synthesis, glycolysis, oxidation of glucose and pentose 
phosphate pathway. It should be noted that hepatic glycolysis provides pyruvate 
principally for lipid synthesis rather than for oxidation. As glucose is the main substrate for 
fatty acid synthesis, hepatic glycolytic enzymes can be considered an extension of the 
lipogenic pathway. Glucose, insulin and parasympathetic nervous system orchestrate these 
glucose metabolic pathways in the fed state, with the aim of maintaining normal levels of 
blood sugar. 
2.1 Glycogen synthesis 
Two enzymes, glycogen synthase and glycogen phosphorylase, control glycogen levels. 
Both enzymes are regulated by phosphorylation and allosteric modulators. Specifically in 
the fed state, insulin activates glycogen synthase (limiting enzyme for glycogen synthesis) 
by promoting its dephosphorylation and, at the same time inhibits glycogen phosphorylase 
(important for glycogen breakdown). Meanwhile, glucose-6-phosphate binding to glycogen 
synthase favours its dephosphorylation, promoting glycogen synthase activity (Bollen, 1998; 
Agius, 2008). As a result, glucose coming from bloodstream fills hepatic glycogen stores. 
2.2 Lipogenesis de novo 
Hepatic lipogenesis is induced upon ingestion of excess carbohydrates to convert extra 
carbohydrates to triglyceride for long-time energy storage. Once inside the hepatocyte, 
glucose enters glycolytic pathway and provides pyruvate, which enters mitochondrion 
where it is converted into acetyl-CoA by pyruvate dehydrogenase. On the other side, in the 
cytoplasm glucose is also oxidized through the pentose phosphate pathway and NADPH is 
obtained. Acetyl-CoA will serve for fatty acid and also cholesterol synthesis. The initial steps 
for fatty acid synthesis are the transfer of acetyl-CoA from mitochondria to the cytoplasm 
and its conversion into malonyl-CoA under the action of the enzyme acetyl-CoA 
carboxylase. Importantly, malonyl-CoA is a regulatory molecule because it inhibits carnitine 
palmitoyltransferase-1, a rate limiting enzyme in ǃ-oxidation of fatty acids. Therefore, 
increasing malonyl-CoA favours lipogenesis. Malonyl-CoA is elongated using NADPH 
under the action of the enzyme fatty acid synthase. Once obtained, fatty acids can be 
esterified with glycerol to form diglyceride and triglyceride. Most of the triglyceride is 
produced for export to the adipose tissue, but in order to be secreted, it must be packaged in 
very low-density lipoprotein (VLDL) particles together with cholesterol, phospholipids and 
apolipoprotein B (Figure 1). 
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Fig. 1. Scheme of de novo lipogenesis from glucose. Once inside the hepatocyte,  
glucose is metabolized on one hand through glycolysis to pyruvate (GK means  
glucokinase; PFK-2, 6, phosphofructo-2-kinase/fructose-2,6-bisphosphatase; L-PK, liver-
pyruvate kinase). On the other hand, glucose is oxidized through pentose phosphate 
pathway to obtain NADPH (G6P-DH means glucose-6-phosphate dehydrogenase;  
6-PGDH, 6-phosphogluconate dehydrogenase). Pyruvate enters the mitochondrion to  
obtain citrate (PDH means, pyruvate dehydrogenase; MDH, malate dehydrogenase and EM, 
malic enzyme). De novo synthesis of fatty acids starts with citrate (ATP-CL means ATP 
citrate lyase; ACC, acetyl-CoA carboxylase) and after suffering elongation and desaturation 
reactions (ELOVL6 means elongase that catalyzes the conversion of palmitate to stearate; 
SCD-1, stearoyl-coenzyme A desaturase), fatty acids are converted to triglyceride (TAG) 
(GPAT means glycerol-3-phosphate acyltransferase; DGAT, diacylglycerol acyltransferase). 
Triglyceride can be stored in the liver but are mostly packaged into VLDL (very low-density 
lipoprotein) and secreted to bloodstream (MTP means microsomal triglyceride transfer 
protein). Original artwork. 
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In mammals, hepatic lipogenesis is controlled by several transcription factors, mainly 
SREBP-1c (sterol regulatory element binding protein 1c) and ChREBP (carbohydrate-
responsive element-binding protein), but also by PPAR-Ǆ (peroxisome proliferator-activated 
receptor gamma), LXR-ǂ (liver X receptor alpha) and XBP1, all of them regulated by 
nutritional and hormonal conditions.  
SREBP-1c plays a major role in the induction of lipogenic genes by insulin. SREBP-1c is a 
member of the bZIP transcription factor family that was originally identified as a mediator 
of sterol signaling (Wang, 1994), and is produced as a precursor form that reside in the 
endoplasmic reticulum in an inactive state. On one hand insulin stimulates SREBP-1c gene 
transcription, and on the other hand, induces the maturation of SREBP-1c precursor 
(Shimomura, 1998). Mature SREBP-1c moves to nucleus and activates transcription of 
several lipogenic genes with SRE (sterol regulatory elements) sequences in their promoters, 
for instance fatty acid synthase (FAS), stearoyl-Coenzyme A desaturase 1 (SCD-1), etc. 
(Figure 2) (Foretz, 1999; Ferre, 2010). 
Glucose regulates genes of glycolytic and lipogenic pathways by activating ChREBP (Iizuka, 
2008). ChREBP is a transcription factor that binds to ChoRE sequences present in the 
promoter of ACC (acetyl Coenzyme-A carboxylase), fatty acid synthase (FAS), stearoyl-
Coenzyme A desaturase 1 (SCD-1), L-pyruvate kinase (L-PK), etc. (Uyeda, 2006). Under 
basal conditions, ChREBP is phosphorylated at Ser196 and remains in the cytosol. When 
glycaemia increase, glucose enters the hepatocyte and is metabolized. Therefore there is an 
increase in some glucose metabolites such as xylulose-5P, which promotes ChREBP 
dephosphorylation (Kabashima, 2003). Then, ChREBP rapidly moves to the nucleus and will 
activate transcription of its target genes (Figure 2). 
SREBP-1c and ChREBP are also transcriptionally activated by liver X receptor apha (LXR-ǂ), 
which could be a glucose sensor although it is controversial (Mitro, 2007; Denechaud, 2008). 
LXR-ǂ is classically activated by oxysterols and it is important for the transcription of some 
lipogenic genes, a part form SREBP-1c and ChREBP, since their promoters contain LXRE 
(LXR response element) sequences (Chen, 2004; Cha, 2007). 
XBP1, a transcription factor best known as a key regulator of the unfolded protein response 
(UPR), has been surprisingly associated with de novo fatty acid synthesis in the liver. It 
seems to be induced by diet carbohydrates and its deletion in mice causes 
hypocholesterolemia and hypotriglyceridemia, attributed to diminished hepatic lipid 
production (Lee, 2008). But, there are still some questions about its function to answer: what 
is its binding site in the promoter regions of these genes? Does it act alone or in partnership 
with other known transcription factors such as SREBP, ChREBP and LXR?  
In summary, hepatic lipogenesis is regulated by several transcription factors that may 
probably work synergistically (Figure 2). With this complex system, carbons from glucose 
can be directed to fatty acid synthesis only when there is substrate availability and glycogen 
depots have been replenished. Altered fatty acid synthesis in the liver can lead to changes in 
lipid secretion, and consequently to dyslipidemia (Ginsberg, 2006). 
2.3 Inhibition of hepatic glucose production 
During fasting, liver produces glucose that enters bloodstream in order to maintain 
glycaemia, ensuring fuel supply for brain and red blood cells. But after a meal, when diet 
glucose arrives, hepatocytes must switch glucose production to glucose uptake. Insulin and 
high glucose levels coordinate the inhibition of glycogenolysis and gluconeogenesis (glucose 
producing pathways).  
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Fig. 2. Main regulatory mechanisms of hepatic metabolism in fed state. Insulin and glucose 
direct gene transcription to switch from glucose producing pathways to glucose uptake and 
storage. Briefly, insulin signaling promotes the phosphorylation of FOXO1 that results in its 
nuclear exclusion and proteasome degradation; consequently, transcription of 
gluconeogenic genes is inhibited. Besides, insulin stimulates transcription of lipogenic genes 
through SREBP-1c activation and probably through LXR-ǂ, as well. Finally, insulin signaling 
causes activation of glycogen synthase function. Glucose also controls allostericaly glycogen 
synthesis and promote transcription of lipogenic genes via activation of ChREBP. IR means 
insulin receptor, IRS, insulin receptor substrate; PI3K, phosphoinositide 3-kinse; AKT, 
Ser/Thr protein kinase; GSK3-ǃ, glycogen synthase kinase 3.beta; FOXO1, forkhead box O1; 
PCK, protein kinase C; LXR, liver X receptor; SREBP-1c, sterol regulatory element binding 
protein 1c; ChREBP, carbohydrate response element binding protein; GS, glycogen synthase; 
GP, glycogen phosphorylase; GK, glucokinase; PP2A, protein phosphatase 2A); IRE, insulin 
response element; LXRE liver X receptor response element; SRE, sterol regulatory elements; 
ChORE, carbohydrate-response elements; PEPCK-C, cytosolic phosphoenolpyruvate 
carboxykinase; G6Pase, glucose-6-phosphatase; ACC, Acyl-CoA carboxylase; FAS, fatty acid 
synthase; SCD-1, stearoyl-CoA desaturase 1; ELOVL , EM, malic enzyme and L-PK, liver- 
pyruvate kinase. Original artwork. 
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Insulin directly inhibits the transcription of gluconeogenic genes by promoting the 
phosphorylation of FOXO1 (forkhead box O), a transcription factor necessary for the 
induction of gluconeogenesis in conjunction with PGC-1ǂ (PPAR-gamma coactivator 1-
alpha) (Puigserver, 2003). In addition, SREBP-1c promotes the inhibition of some 
gluconeogenic genes. Insulin also represses glycogenolysis by phosphorylating glycogen 
synthase (Bollen, 1998). On the other hand, insulin regulates hepatic glucose production 
indirectly: a) it suppresses lipolysis in adipose tissue causing a reduction in glycerol 
(gluconeogenic substrate) availability; b) it inhibits glucagon secretion in the pancreas; and 
c) it activates hypothalamic pathways important for glucose homeostasis.  
Synergistically with insulin, glucose inhibits glycogenolysis allosterically (Bollen, 1998). 
Glucose inhibition on gluconeogenesis is mediated by glucose metabolites, specifically 
fructose-2,6-bisphosphate (Wu, 2001) and xylulose-5-phosphate (Massillon, 1998).  
3. Glucokinase regulates the fate of glucose carbons in the liver 
In order to enter the lipogenic pathway, glucose must be metabolized. The first and rate-
limiting step is the phosphorylation of glucose at the 6th carbon to obtain glucose-6-
phosphate. This reaction is catalyzed by glucokinase (GK; EC 2.7.1.1), a member of the 
hexokinase family. However, GK differs from other hexokinases in its particular kinetic 
properties: affinity for glucose that is within the physiological plasma concentration range 
(S0.5 for glucose of 8 mM), positive cooperativity for glucose although it is a monomeric 
enzyme, and lack of inhibition by glucose-6-phosphate (Table 1). 
 
 HEXOKINASES 1-3 GLUCOKINASE 
Molecular weight 100 KDa 50 KDa 
Substrates Hexoses Glucose 
S0.5 for glucose < 0.5 mM 8 mM 
Kinetic  Hyperbolic Sigmoidal 
Product inhibition Yes No 
Table 1. Hexokinase family kinetic properties 
As a result of its kinetic characteristics, intracellular glucose phosphorylation rate inside the 
hepatocyte correlates with glycaemia. Hence, GK can be considered an intracellular glucose 
sensor. Consequently, apart from hepatocytes, GK is expressed in glucosensitive cells of the 
pancreas, hypothalamus, anterior pituitary gland, and entero-endocrine K and L cells of the 
gut (Schuit, 2001; Zelent, 2006; Vieira, 2007; Iynedjian, 2009), all of them crucial in the control 
of the whole-body glucose homeostasis. 
Liver contains 99.9% of the body GK. Therefore, is not surprising that this enzyme 
influences intermediary metabolism and energy storage. GK reaction controls the flux of 
glucose through several metabolic pathways: glycolysis, glucose oxidization, glycogenesis, 
triglyceride synthesis, phospholipids and cholesterol synthesis, glycogenolysis and 
gluconeogenesis. For that reason, GK is an enzyme highly regulated in the liver, both at the 
transcriptional and the post-transcriptional level.  
3.1 Regulation of GK activity in the liver 
Gck gene has two distinct promoters and one of them directs gene transcription specifically 
in the liver (Postic, 1995). Hepatic GK expression responds to nutritional changes; it is 
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activated by insulin and inhibited by glucagon. Insulin induction of Gck gene expression is 
through the PI3-kinase/Akt signaling. However, no IRE (insulin response element) has been 
described in Gck promoter, and it is not clear which transcription factor mediates insulin-
directed Gck expression. SREBP-1c is a candidate to mediate insulin-directed expression of 
Gck, although controversial results exist (Foretz, 1999; Gregory, 2006). Probably, SREBP-1c is 
not essential for rapid induction of GK transcription, but it can have a role for long-term 
expression. Other candidates to mediate insulin-dependent expression of Gck gene are the 
complex HIF-ǂ/HNF-4/p300 (Roth, 2004), and ERR-ǂ -estrogen-related receptor alpha- 
(Zhu, 2010). 
GK can be modulated by covalent modifications such as nitrosylation and phosphorylation. 
However, the physiological importance of these modifications is still not determined. More 
importantly, protein interaction affects GK activity and even intracellular distribution. It has 
been described that GK in the liver can interact with GKRP (glucokinase regulatory protein), 
BAD (Bcl-xL/Bcl-2-Associated Death Promoter), PFK-2 (6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase), GKAP (glucokinase-associated protein), etc. (Massa, 2010). From all GK 
protein partners, GKRP is the best studied and has high physiological relevance in the liver.  
3.1.1 Post-transcriptional regulation by GKRP 
GKRP regulation of GK affects both the activity and subcellular localization of the enzyme. 
GKRP is a competitive inhibitor with respect to glucose. Van Shaftingen et al proposed a 
mechanistic model (Van Shaftingen, 2004); GKRP exists in two conformations, one with low 
affinity for GK and the other with high affinity. Fructose-1-phosphate and fructose-6-
phosphate bind to the same binding site in the GKRP protein. When fructose-1-phosphate is 
bound to GKRP, GKRP adopts a conformation with low affinity for GK, and on the contrary, 
when the binding of fructose-6-phosphate to GKRP favours its interaction with GK.  
But, Kamata et al also described that GK can exist in different conformations with different 
affinity for glucose (Kamata, 2004); in the absence of glucose, the enzyme exists in a super-
open conformation thermodynamically stable and with low affinity for substrate. When 
glucose binds to it, there is a conformational change to an open form and next to a closed 
conformation that binds ATP. Then the catalytic cycle completes, after reaction products are 
released, GK can relax to an open or to a super-open conformation, depending on glucose 
concentrations (considering that the open conformation has higher affinity for glucose). GK 
conformation is important for GKRP protein interaction, as it can only take place when GK 
is in the super-open conformation (Anderka, 2008). From these conformational models of 
GKRP and GK, one can extrapolate the exquisite influence of carbohydrate concentration in 
regulating GKRP/GK binding and, consequently, GK phosphorylating activity. 
GKRP also plays a fundamental role in importing GK to the nucleus, as it can be deduced 
from animals null for GKRP that present GK permanently in the cytosol (Farrelly, 1999). At 
low glucose concentrations, GKRP binds to GK and the formation of GKRP/GK complex 
results in entry and sequestration of both proteins in the nucleus of hepatocytes. However, it 
is still not resolved how GK is translocated to the nucleus. On the other hand, in metabolic 
states with high glucose concentrations, accompanied or not by high fructose levels, and 
sufficient ATP, there is the dissociation of the GKRP/GK complex. GK has a nuclear export 
signal sequence. Therefore, once dissociated from the complex, GK can be exported to the 
cytoplasm (Shiota, 1999). Insulin also favours the dissociation of the complex. 
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The physiological function of GKRP consists of inhibiting GK activity by sequestering it to the 
nucleus. GKRP binding also serves to stabilize GK protein and protect it from degradation. 
Thus, thanks to GKRP a big reservoir of GK exists in the nucleus of the hepatocyte at low 
glucose concentration. After a meal, this reservoir of GK can be rapidly mobilized 
(translocation is complete within 30 minutes) to the cytosol in order to promote glucose uptake 
and storage in the liver. This regulation process is much more fast and efficient than the 
synthesis de novo of GK promoted by insulin. Conversely, when glucose uptake has finished, 
GK returns to the nucleus in order to save energy because, on one hand, this translocation 
avoids the futile cycle between glucose and glucose-6-phosphate, and on the other hand, it 
ends the glucose signal generated by GK activity that activate transcription of glycolytic and 
lipogenic genes (Figure 3). The consequence of GK translocation to the nucleus in the post-
absorptive state is the induction of glycogenolysis and gluconeogenesis. 
 
Hepatocyte
Nucleus
A B
Nucleus
Legend:
GK
GKRP
Glucose
Fructose
Insulin
Hepatocyte
 
Fig. 3. Subcellular localization of GK regulated by GKRP. (A) During fasting, GK is 
sequestered in the nucleus where it remains bound to GKRP and inactive. After a meal, 
nutritional signals (i.e. insulin, glucose and fructose) induce the dissociation of the 
GK/GKRP complex and free GK translocates to the cytosol. Original artwork. 
To summarize, thanks to its kinetic properties and its subtle regulation, GK enables the liver 
to adapt its metabolism for glucose uptake or glucose production as required, and 
consequently to regulate energy homeostasis.  
3.2 GK modulation in the liver: impact on carbohydrate and lipid metabolism  
Numerous natural mutations in GK gene have been associated to disease (Gloyn, 2003 & 
Osbak, 2009), reinforcing the concept that it is a crucial enzyme in the control of whole-body 
glucose homeostasis. Mutations that cause decrease or loss of GK activity are associated to 
maturity onset diabetes of the young-2 (MODY-2) or to permanent neonatal diabetes 
mellitus (PNDM). In diabetes, as a result of impairment in insulin secretion, the capacity of 
the liver to uptake glucose is diminished. On the other hand, activating mutations of GK 
cause persistent hyperinsulinemic hypoglycemia in infancy (PHHI). The phenotype of all 
these pathologies is mainly dominated by GK function in the pancreatic ǃ-cell, where it 
regulates glucose-dependent insulin secretion. As insulin controls hepatic GK transcription 
and influences GKRP regulation, it is difficult to elucidate which are the specific 
consequences of these mutations on hepatic GK independently of insulin.  
Some animal models have been developed to study the specific role of liver GK on 
metabolism. 
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3.2.1 Genetic suppression of hepatic GK 
A liver specific GK knock-out was obtained using the LoxP-Cre system (Postic, 1999). 
Transgenic mice showed mild hyperglycemia and hyperinsulinemia in basal conditions, 
without changes in hepatic glycogen, plasma non-esterified fatty acids, triglycerides or ǃ-
hydroxybutyrate. In hyperglycaemic clamp studies, reduced hepatic glucose uptake and 
glycogen levels were observed in KO animals; however, results on lipid profile were not 
provided. 
3.2.2 Genetic overexpression of GK in the liver 
Several liver GK gain-of-function studies, both using transgenic animals and by means of 
adenovirus gene transfer, have been performed in healthy animals and models of diabetes 
such as streptozotocin induced type I and type II induced by ingestion of high fat/high 
carbohydrate diet. Due to heterogeneity, these studies will be examined according to the 
animal model and analysis conditions. 
a. Overexpression of GK in the liver of fed, healthy animals is summarized in Table 2 
(Ferre, 1996a, 1996b, 2003; O’Doherty, 1999; Scott, 2003).  
 
Study variables Ferre 1996a, 1996b 
Ferre 2003 
O’Doherty 1999; 
Scott 2003 
Animal model Mus musculus Rattus norvegicus 
Transgenic Adenoviral gene transfer 
PEPCK-C promoter CMV promoter 
GK activity over 
control 
x 2 x 3 x 6.4 
Age at analysis 2 months 12 months 5 days post-injection 
(Rats 200-250 g) 
Glycaemia decrease - no change Decrease 
Blood lactate - - increase Increase 
Blood triglycerides ~ increase - ~ increase Increase 
NEFA ~ increase - no change increase 
Insulin decrease increase no change decrease 
Hepatic glucose-6-P increase ~ increase - - 
Hepatic glycogen increase decrease no change no change 
Hepatic triglycerides no change increase - - 
Modulation of 
enzymes and 
transcription factors 
↑ L-PK 
↓PEPCK-C, 
GLUT-2, TAT 
- ↑ L-PK, ACC1, 
FAS, G6Pase. 
No change in 
PEPCK-K 
- 
Table 2. Hepatic GK overexpression studies in healthy fed animals. Comments: decrease, 
increase and no change are referred to control group. “~” means no statistically significant; 
“-“, no determined; “CMV”, cytomegalovirus; “PEPCK-C”, cytosolic phosphoenolpyruvate 
carboxykinase; “L-PK”, liver pyruvate kinase; “TAT”, tyrosine aminotransferase; “ACC1”, 
Acetyl-Coenzyme A carboxylase 1; “FAS”, fatty acid synthase; and “G6Pase”, glucose-6 
phosphatase. 
In these models, enhancing hepatic glucose uptake by GK overexpression results in a direct 
reduction of glycaemia. As a consequence of lower blood glucose levels, pancreatic ǃ-cell 
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secretes less insulin. Therefore, a decrease in insulinemia is a secondary effect of increasing 
hepatic GK activity. But, O’Doherty et al demonstrate that the influence of GK activity on 
blood glucose and insulin levels could be dose-dependent, as it occurs only with high doses 
of their transgene. In the hepatocyte, glucose-6-phosphate derived from GK activity is 
directed to glycogen synthesis and, consequently, hepatic glycogen levels are increased in 
the study by Ferre et al. However, glycogen content is not modified by GK overexpression 
in the study of O’Doherty et al, maybe for intrinsic limitations. In both animal models, 
increasing GK activity results in glucose signaling that activates transcription of glycolytic 
and lipogenic genes. Lipogenic proteins together with high availability of citrate and ATP 
(derived from augmented glucose metabolism) lead to enhanced de novo lipogenesis in the 
liver, and consequently, higher secretion of VLDL to bloodstream that could explain the 
observed increase in blood triglycerides. Augmented blood fatty acids might be explained 
by insulin levels; low levels of this hormone result in low inhibition of lipolysis in the 
adipose tissue, and consequently fatty acids raise in the bloodstream. Importantly,  
Ferre et al show that long-term GK overexpression drives to hyperinsulinemia and hepatic 
steatosis. 
b. Studies of GK overexpression in the liver of fasted, healthy mice are listed in Table 3 
(Hariharan, 1997; O’Doherty, 1999; Desai, 2001; Ferre, 2003 & Scott, 2003) 
 
 
Study variables Hariharan 
1997 
Desai 2001 Ferre 2003 O'Doherty 1999 
Scott 2003 
Animal model M. musculus M. musculus M. musculus R. norvegicus 
 Transgenic Adenovirus Transgenic Adenovirus 
Promoter apoA1-SV40 RSV PEPCK-C CMV 
GK activity over 
control 
x5 x1.5 x2 x2.1 or x3 
Age at analysis 5 weeks 3 weeks post-
injection 
12 months 4-5 days post-
injection 
Glycaemia Decrease no change - no change 
Blood lactate Decrease no change - ~ decrease 
Blood triglycerides no change no change increase increase 
NEFA ~ increase no change - no change 
Insulin Decrease decrease increase no change 
Hepatic glucose-6-P - - ~ increase - 
Hepatic glycogen - - no change increase 
Hepatic triglycerides - - increase - 
Modulation of 
enzymes and 
transcription factors 
- - - ↑ L-PK, ACC1 
No change: 
PEPCK-C, PFK-2 
Table 3. Hepatic GK overexpression studies in healthy fasted animals. Comments: decrease, 
increase and no change are referred to control group. “~” means no statistically significant; “-“, 
no determined; “CMV”, cytomegalovirus; "RSV", rose sarcoma virus; "apoA1-SV40", 
apolipoprotein A1 enhancer and simian vacuolating virus 40 promoter; “PEPCK-C”, cytosolic 
phosphoenolpyruvate carboxykinase; “L-PK”, liver pyruvate kinase; “ACC1”, Acetyl-
Coenzyme A carboxylase 1; “PFK-2", 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. 
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In fast state, the influence of hepatic GK overexpression on glycaemia is not clear. Hariharan 
et al showed a decrease in glycaemia, accompanied by a decrease in insulinemia that could 
explain a reduction of glycolysis in skeletal muscle, causing the observed decline in serum 
lactate. Low insulin levels can also explain the increment of blood fatty acids. Interestingly, 
20-weeks old mice were smaller than controls and presented reduced body mass index.  
On the contrary, long-term analysis of transgenic mice developed by Ferre et al showed  
that increasing GK activity in the liver lead to hepatic steatosis, hyperglycemia, 
hyperinsulinemia, obesity and insulin resistance. On the other hand, adenoviral gene 
transfer models for hepatic GK overexpression in fasting revealed induction of lipogenesis 
and consequently a tendency to increase blood triglycerides, without affecting glycaemia.  
c. Studies on hepatic GK overexpression in the context of type 1 diabetes mellitus: This is 
an autoimmune disease with specific destruction of insulin-producing ǃ-cells in the 
pancreas, and results in loss of insulin production. As insulin stimulates the 
transcription of Gck gene in the liver, type 1 diabetic subjects do not have GK protein in 
their livers and consequently hepatic glucose metabolism is impaired. Gene therapy has 
been tested to restore liver glucose uptake capacity by increasing hepatic GK protein 
(Ferre, 1996a; Morral, 2002, 2007). In type 1 diabetic liver, all models present a similar 
phenotype. When restoring glucose signaling in diabetic hepatocytes via GK, glucose 
catabolic pathways are induced and, on the contrary, hepatic glucose production is 
inhibited. Consequently there is a reduction of diabetic hyperglycemia accompanied by 
incremented hepatic glycogen depots and de novo lipogenesis. Decreasing blood 
glucose levels forces muscle and adipose tissue to use fatty acids as energetic substrates, 
and in consequence, serum fatty acids are decreased in type 1 diabetic mice expressing 
GK in the liver. Lower blood fatty acids, together with increased glucose metabolism in 
the liver, inhibit hepatic  ǃ-oxidation of fatty acids. Therefore, these models suggest that 
hepatic overexpression of GK in type 1 diabetes leads to normoglycaemia thanks to 
increments in hepatic glucose uptake and fatty acid oxidation in peripheral tissues. 
d. Finally, hepatic GK overexpression in the context of type 2 diabetes: type 2 diabetes is a 
complex metabolic disorder caused by two physiologic defects: insulin resistance in 
combination with insulin secretion deficiency. Type 2 diabetes is characterized by 
glucose metabolism alterations such as failure of insulin to inhibit hepatic 
gluconeogenesis and impaired skeletal muscle glucose uptake. However, lipid 
metabolism is also altered. This is often reflected by increased circulating free fatty 
acids and triglycerides together with increased fat accumulation in non-adipose tissues. 
Thus, changes in the equilibrium between glucose and fatty acid metabolism in liver 
and muscle could be responsible for glucose homeostasis alterations. Obesity, 
hyperinsulinemia, in combination with hyperglycemia, inhibits fatty acid oxidation in 
many tissues. As a result, lipogenesis is favored over fatty acid oxidation leading to an 
increase in fat accumulation and a decrease in energy expenditure. A hypothetical 
strategy for type 2 diabetes therapy is increasing glucokinase activity, with the aim of 
enhancing glucose uptake in the liver that could contribute to gluconeogenesis 
inhibition with consequent restoration of glycaemia. If glycaemia is restored, plasma 
insulin levels could be secondarily lowered and it could be able to elevate energy 
expenditure and reduce obesity.  
However, liver GK activity is increased in mild type 2 diabetes, but diminished in morbid 
obese diabetic patients. Animal diabetic models linked to obesity, show that GK deficiency in 
the liver occurs only in the case of obesity, and in severe or long-term forms of the disease. 
Although hepatic GK expression is different depending on disease stage, some strategies 
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based on increasing GK activity in the liver have been tested in some models of high fat diet 
induced type 2 diabetes (Desai, 2001 & Ferre, 2003) , in obesity models (Wu, 2005 & Torres, 
2009) and in transgenic mice with hepatic insulin resistance (Okamoto, 2007). All these studies 
have in common that the increase in hepatic GK activity produces glycaemia normalization. 
Hepatic GK, through glycolysis and glycogenesis activation, increases blood glucose clearance 
while it inhibits hepatic glucose production. On the other hand, liver GK activity results in 
increased malonyl-CoA, a lipogenic substrate and inhibitor of ǃ-oxidation. It is difficult to 
draw clear conclusions when evaluating consequences of liver GK overexpression on lipid 
metabolism in type 2 diabetic models. Wu et al report an expected increase in hepatic and 
serum triglycerides, together with higher serum fatty acids. However, Wu et al report that, 
although hepatic fatty acid ǃ-oxidation was decreased, muscle increased fatty acid oxidation as 
a consequence of lower glycaemia and insulinemia. Conversely, Desai et al showed no 
changes in hepatic and serum lipid levels. Otherwise, Torres et al & Okamoto et al obtained an 
increase in serum triglycerides with no changes in fatty acid levels. The most striking model is 
presented by Ferre et al: under high fat diet, liver GK-transgenic mice became insulin resistant 
faster than controls and showed hepatic steatosis. It contrasts with results obtained in GK gene 
locus transgenic mice (Shiota, 2001). Besides exhibiting a reduction of the blood glucose 
concentration, mice with a greater than normal amount of GK also exhibited a dramatic 
resistance to the development of hyperglycemia and hyperinsulinemia normally brought on 
by consumption of a high fat diet.  
Taken together, all these models have convincingly demonstrated that increasing GK protein 
in the liver leads to a direct reduction of glycaemia, but sometimes it can be accompanied with 
the risk of serious alterations in lipid metabolism deriving in hepatic steatosis and/or overt 
dyslipidemia. This aspect is essential when considering the possibility of using GK 
overexpression in the liver for diabetes therapy. At this point, it would be important to find 
out which are the causes of the different phenotypes observed in those animal models of 
hepatic GK overexpression previously described. There are several possible reasons: 
a. Species-specific results: one possibility is that GK overexpression in mouse liver may be 
more effective stimulating glucose disposal than the same degree of expression in a 
larger animal such as rat. 
b. Side-effects of gene transfer technology: when using adenoviral gene transfer, 
adenoviruses involve per se hepatic metabolic changes. When using transgenic, germ-
line manipulated animals overexpress GK throughout life, including intrauterine life, 
possibly resulting in compensatory changes in insulin secretion, insulin action, or in 
other metabolic variables that do not occur with acute manipulation of GK via 
adenovirus technology. 
c. Promoter that directs transgene expression can affect two important variables. On one 
hand, taking into account the metabolic hepatic zonation concept (Jungermann, 1995), the 
promoter determines which set of hepatocytes express the transgene. It is well known that 
physiological GK expression predominates in the perivenous area of the liver (Moorman, 
1991; Jungerman, 1995 & Jungerman, 2000). However, most studies of hepatic GK gain of 
function did not use perivenous promoters. For instance, Ferre et al used a PEPCK 
promoter that directs the transgene to the periportal area of the liver, specialized in 
gluconeogenesis. In contrast, RSV or CMV promoters are ubiquitous promoters that 
transfect both perivenous and periportal hepatocytes. On the other hand, promoter directs 
the regulation of transgene expression by nutrients and hormones. For instance, GK under 
the PEPCK promoter is expressed under glucagon signaling and is inhibited by glucose 
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and insulin. Therefore, hepatic GK transgenic mice described by Ferre et al express GK at 
the periportal area of the liver during fasting, and not in fed state.  
d. Transgene dose: Desai et al and O'Doherty et al described different metabolic impact of 
hepatic GK overexpression depending on the dose of transgene that they used. 
In our laboratory we aimed to re-examine the conclusions of these studies and the 
differentiated effects that GK activity could have on the metabolism, clearly differentiated, of 
periportal and perivenous hepatocytes. To evaluate the issue, we have developed a 
hydrodynamic gene transfer technique that served us to pursuit GK overexpression studies 
exclusively in perivenous liver (Liu, 1999; Zhang, 1999; Gomez-Valades, 2006; Budker, 2006 & 
Suda, 2007). With the injection of a plasmid for green fluorescent protein (GFP) and 
immunohistochemistry for PEPCK (periportal marker), we could visualize that hydrodynamic 
injection generate two separate populations of hepatocytes: green hepatocytes that expressed 
GFP and red hepatocytes showing PEPCK-C staining (Figure 4). We could conclude that in our 
conditions the hydrodynamic gene transfer technique delivered the transgene only in the 
hepatocytes surrounding the central vein of the liver acinus. 
 
A B C
 
Fig. 4. Visualization of liver transfection achieved with adenoviral and hydrodynamic gene 
transfer techniques. (A) Healthy mice were injected with 5.5·109 IU of an adenovirus that 
codified for the green fluorescent protein (GFP). Green fluorescence was observed in liver 
sections (200X), demonstrating a homogeneous presence of the transgene all over the liver 
acinus. (B) A plasmid for GFP was hydrodynamically injected to healthy mice and, as it can 
see appreciated in liver sections, resulted in non-homogenous green fluorescence signal. (C) 
Slices from hydrodynamically-injected mice were immunostained for PEPCK-C (red signal), 
a periportal marker. 
Our results represent the first attempt to overexpress pGK in perivenous hepatocytes. The 
first approach was the hydrodynamic injection of a plasmid with the Gck gene to healthy 
mice (Vidal-Alabró; publication pending). Forty-eight hours post-injection, increased GK in 
perivenous hepatocytes had clear effects on glucose homeostasis (Figure 5A). There was a 
reduction of glycaemia and insulinemia in the fed state, probably as a direct consequence of 
increased hepatic glucose uptake. Therefore perivenous GK gain of function reproduced 
results of periportal GK (Ferre, 1996), and liver-homogeneous GK overexpression 
(O'Doherty, 1999; Desai, 2001 & Scott, 2003). However, 16 hours-fasted mice did not show 
differences in blood glucose and insulin levels (data not shown), as Desai et al and 
O'Doherty et al had obtained with adenoviral GK transfer. Fifty days post-injection, 
perivenous GK overexpressing-mice presented blood glucose levels similar to control 
animals but accompanied by hyperinsulinism (Figure 5B). Long-term augmented GK 
activity in perivenous liver resulted in hepatic insulin resistance, since mice presented a 
phenotype very similar to liver-specific insulin receptor knock-out mice named LIRKO 
(Michael, 2000). Briefly, hyperinsulinism was probably due to reduced hepatic insulin 
clearance. Since peripheral tissues were still insulin-sensitive, hyperinsulinism inhibited 
lipolysis and induced lipogenesis in adipose tissue. Adipose tissue function together with 
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reduced hepatic lipogenesis de novo could explain the observed decrease in circulating 
triglycerides and free fatty acids. Although having increased GK activity in the liver, neither 
glycogen synthesis nor glycolysis was stimulated in those mice. Besides, gluconeogenesis 
was not inhibited in fed state. Therefore, considering the bibliography, our perivenous 
model resembled transgenic mice that expressed GK transgene under PEPCK-C promoter at 
periportal hepatocytes (Ferre, 2003). However, periportal GK overexpressing model showed 
whole-body insulin resistance linked to obesity and hepatic steatosis. It must be considered 
that their analysis was in 12 months old mice. If the study was extended to 12 months, we 
would be able to tell if hepatic insulin resistance observed in our mice model leads to 
general insulin resistance or, on the contrary, confirm its resemblance to LIRKO animals.  
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Fig. 5. Analysis of GK-overexpressing healthy mice. (A) Shows glycaemia and insulinemia, 
48 hours post-injection of the plasmid that contained the GK gene. Columns represent 
media ± standard error. (B) 50 days post-injection results on serum nutrients (glucose, free 
fatty acids and triglycerides) together with insulin levels are represented. (C) After 50 days 
post-injection, expression of glycolytic and gluconeogenic genes from liver were analyzed 
by Real-Time PCR. Calculations were done following ΔΔCt algorithm (Applied Biosystems), 
using ǃ-microglobulin gene expression as a housekeeping gene. (D) The same for lipogenic 
and lipolysis genes. * p<0.05 and **p< 0.01 vs control, determined by t-Student.  
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In the context of type 1 diabetes induced with streptozotocin, perivenous liver GK gain of 
function restored hepatic glucose uptake and reduced gluconeogenesis. Therefore, typical 
increases in hepatic glucose depots (glycogen, triglyceride) occurred and resulted in a 
reduction of diabetic glycaemia, albeit small. But, perivenous GK expressing mice showed a 
significant increase in triglyceride and free fatty acid serum concentration, and hepatic 
lipids (Figure 6) (Vidal-Alabró; publication pending). Therefore our work in type 1 diabetes 
model reproduces those of periportal GK overexpression (Ferre, 1996a) and those of liver 
homogeneous GK overexpression (Morral, 2002, 2007) in terms of glycaemia. However, our 
results on lipid metabolism are more deleterious, probably because perivenous hepatocytes 
have higher lipogenic potential than periportal hepatocytes (Jungermann, 1995). 
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Fig. 6. Analysis of perivenous GK overexpression in type 1 diabetic mice. (A) Shows 
glycaemia, serum triglycerides and free fatty acids, 48 hours post-injection of the plasmid 
that contained the GK gene. Columns represent media ± standard error. (B) Hepatic glucose 
storage was evaluated by measuring glycogen and triglyceride levels. (C) Expression of 
lipogenic genes in the liver was analyzed by Real-Time PCR. Calculations were done 
following ΔΔCt algorithm (Applied Biosystems), using ǃ-microglobulin gene expression as a 
housekeeping gene. (D) The same for gluconeogenic and lipolysis genes. * p<0.05, **p< 0.01 
and *** p<0.001 vs control, determined by t-Student.  
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All in all, our review of the literature together with our own results on the subject will 
convey that pGK-overexpression in the liver, independent of zonation, will result in changes 
in glycaemia but with the risk of non-desirable lipid alterations and insulin resistance. 
However, several undetermined factors influence the results obtained in GK overexpression 
studies, reinforcing the concept that hepatic GK is a key regulator of whole-body 
homeostasis, so that little changes in its activity and/or in its regulation affect glucose and 
lipid metabolism.  
4. GKRP modulates the impact of GK activity on glucose and lipid 
homeostasis 
GKRP is the best-known regulator of the hepatic GK at the post-transcriptional level. 
Therefore, impairments in GKRP should affect GK and consequently glucose metabolism, 
since GK plays a central role in glucose homeostasis. Nevertheless, mutations in the GKRP 
gene (Gckr) that caused disease or alterations in glucose metabolism have never been 
described until now. Recently, several whole-genome analysis have associated 
polymorphisms in the Gckr gene with fast hypoglycemia and increased serum triglyceride 
in humans, even though these subjects have reduced risk to type 2 diabetes (Køster, 2005; 
Sparsø, 2007; Vaxillaire, 2008; Orho-Melander, 2008 & Beer, 2009). The mechanism 
underlying this phenotype seems to be a reduction in GK inhibition by the variant 
regulatory protein (Beer, 2009). But, before exploring this issue it should be convenient to 
consider some aspects of GKRP biology. 
Although GKRP research has been focused in the liver, there are evidences that the GKRP 
protein is also present in hypothalamic neurons (Schuit, 2001; Alvarez, 2002 & Roncero, 
2009). GK/GKRP system in the hypothalamus could play a role in glucose-sensing 
important for the regulation of energy homeostasis by balancing energy intake, expenditure 
and storage. On the other hand, there is some controversy in the literature as to whether 
GKRP also regulates GK in pancreatic ǃ-cells. The vast majority of studies state that GKRP is 
not expressed in rodent ǃ-cells. However, it has been demonstrated that human islets 
express GKRP at very low levels (Beer, 2009). This issue should be revisited because of the 
recent publication of several genome-wide association studies that associate GK, GCKR, 
G6PC2, MTNR1B with type 2 diabetes risk linked to ǃ-cell function (Reiling, 2009 & Bonetti, 
2011). Whether, ǃ-cell GK function is affected directly by a hypothetic pancreatic GKRP, or 
indirectly by liver GKRP impaired activity, still needs clarification. Another question that 
remains to be resolved is whether GKRP is also expressed and functional in other GK 
expressing cells, for instance, in the gut and in the pituitary gland. 
Consequently, when considering studies of genome-wide association, mutant GKRP protein 
might affect GK activity in the brain, in the liver and perhaps in the ǃ-cell. Therefore it is 
difficult to explain the phenotype only taking into account the hepatic GK/GKRP system. 
The same occurs with the characterization of GKRP-deficient mice (Farrelly, 2002 & 
Grimsby, 2000). GKRP knock-out mice models, whether heterozygous or homozygous, had 
normal weight. Interestingly focusing in liver analysis, those mice displayed reduced 
production of hepatic GK protein while having the same levels of GK mRNA than control 
animals, and GK protein was localized exclusively in the cytoplasm. That showed the 
importance of hepatic GKRP in stabilizing and protecting the intracellular GK pool. These 
animal models exhibited impaired postprandial glycemic control, with lower hepatic 
glycogen content and lack of inhibition of PEPCK-C gene expression, albeit with no 
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noteworthy loss in insulin secretion or changes in fasting blood glucose concentrations. 
Moreover, when challenged with a high-sucrose/high-fat diet the knock-out and normal 
mice gained body weight at a similar rate but the knock-out mice were hyperglycaemic and 
hyperinsulinemic. Importantly, no changes in plasma triglycerides and non-esterified fatty 
acids were observed in basal conditions as well as with a high-sucrose/high-fat diet. In 
summary, absence of GKRP results in decreased hepatic GK protein content, affecting 
glucose metabolism without disturbing lipid parameters.  
On the other hand, GKRP gain of function in the liver has also been assessed. In vitro 
studies with HepG2 cells simultaneously transduced with an adenoviral vector expressing 
GKRP and another adenoviral vector for GK had significantly elevated GK protein and 
activity levels compared with cells transduced with the GK adenovirus alone (Slosberg, 
2001). These data suggest that GKRP serves to stabilize and protect a pool of GK protein 
(i.e., extend half-life), and is consistent with data obtained in GKRP knock-out studies. But 
in vivo studies revealed a more complicated situation. Adenoviral-mediated hepatic 
overproduction of GKRP in mice with high-fat diet-induced diabetes resulted in 23% 
decrease in GK enzymatic activity. Although reduction of GK activity is commonly 
associated to diabetes, hepatic GKRP-expressing mice had improved fasting and glucose-
induced glycaemia with a concomitant increase in insulin sensitivity and TAG levels, and a 
decrease in leptin levels. A possible explanation for discrepancies between in vivo and in 
vitro results on GK levels when overexpressing GKRP is that GK expression in vivo is 
influenced by insulin and other physiological regulators. To understand how decreased GK 
activity improved type 2 diabetes phenotype in this model, a possibility is that GK activity 
may be applied in a more efficient manner toward metabolizing blood glucose. The 
subcellular compartmentalization by scaffolding proteins of enzymes or signaling proteins 
into clusters is often used as a means of increasing system efficiencies. 
Coming back to genome-wide studies that associate Gckr with fast hypoglycemia and high 
triglycerides, Beer et al reported that P446L-GKRP has reduced regulation by physiological 
concentrations of fructose-6-phosphate, resulting indirectly in increased GK activity (Beer, 
2009). They predicted that this increased GK activity in the liver enhanced glycolytic flux, 
promoting hepatic glucose metabolism and elevating concentrations of malonyl-CoA, a 
substrate for de novo lipogenesis, providing a mutational mechanism for the reported 
association of this variant with raised triglycerides and lower glucose levels. However, their 
predictions are conflictive with in vivo studies by Slosberg et al (Slosberg, 2001), since GKRP 
gain of function reduced hepatic GK activity and also resulted in a decrease of blood glucose 
levels accompanied by an increase of blood triglycerides. Therefore, any other 
undetermined factor/s must exist to really understand the complex physiology of the 
GK/GKRP system. Another possibility is that brain P446L-GKRP and ǃ-cell P446L-GKRP (if 
existent) may exert determinant influences on phenotype.  
Another study that may bring light to this issue, relates to defects in glucokinase 
translocation identified in Zucker diabetic fatty (ZDF) (Fujimoto, 2004 & Shin, 2007). 
Although having normal GK protein content, GK was predominantly localized in the 
nucleus regardless of plasma glucose and insulin levels. Nevertheless, sorbitol restored GK 
translocation. Clearly, there must be two distinct mechanisms bringing about the 
dissociation of GK from GKRP. How they are related and what differentiate them are 
questions currently under investigation. Since this defect was discovered in early stage of 
diabetes, it could cause of the progression to diabetes seen in the adult ZDF rat. 
Consistently, a MODY-2 mutation in the Gck gene has been reported to increase the physical 
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interaction of GK and GKRP (García-Herrero, 2007). But, again these data are in conflict 
with other studies that reported some new GK mutations causing MODY-2 that reduced GK 
inhibition by GKRP (Veiga-da-Cunha, 1996; Gloyn, 2005 & Sagen, 2006). Once more, it is 
difficult to draw conclusions, but the importance of proper GK/GKRP function on 
metabolism and disease is reinforced, as subtle changes in its activity and/or regulation lead 
to contrary phenotypes.  
Several naturally occurring activating mutations have been described that are localized at 
the same region where synthetic GK activators bind (Kamata, 2004; Heredia, 2006 & 
Matschinsky, 2009). Both activating mutations and synthetic activators stabilize the open 
conformation of the GK protein, resulting in higher affinity for glucose and a reduction of 
the interaction between GK and GKRP, since the super-open conformation of the enzyme 
(inactive) is not possible. In humans, activation of GK by naturally occurring mutations is 
associated to persistent hyperinsulinemic hypoglycemia of the infancy (PHHI), syndrome 
with a heterogeneous phenotype even in the same family but generally with a normal lipid 
profile. On the other hand, GK activation through administration of GK activation drugs has 
been tested for their potential in the therapy of type 2 diabetes, considering principally their 
capacity to increase glucose-stimulated insulin release at the ǃ-cell (Grimsby, 2003; 
Brocklehurst, 2004; Efanov, 2005; Leighton, 2005; Coope, 2006 & Matschinsky, 2009). Whole-
body effects of glucokinase activator drugs demonstrated a dose-dependent reduction of 
glycaemia, associated with increased insulin secretion in the pancreas and net glucose 
uptake in the liver. Besides, the administration of a GK activator prevented the development 
of diabetes in a diet-induced obesity animal model (Grimsby, 2003). Surprisingly, most in 
vivo studies with GK activators drugs do not show the lipid profile (Grimsby, 2003; 
Brocklehurst, 2004; Efanov, 2005; Leighton, 2005 & Coope, 2006), except one where 
treatment of ob/ob mice with GK activator PSN-GK1 did not produce any significant 
change blood lipids (Fyfe, 2007).  
With all this puzzling background, we intended to study the expression of an activated 
mutant form of GK with the aim to decipher the metabolic consequences in the liver of 
having a GK not regulated by GKRP, with theoretical antidiabetic properties. Particularly 
we proposed the overexpression of glucokinase A456V (identified in patients of persistent 
hyperinsulinemic hypoglycemia of the infant), with a S0.5 for glucose of 3 mM instead of 8 
mM for the wild-type enzyme (Christesen, 2002), and without GKRP regulation (Heredia, 
2006). We postulated that GK-A456V overexpression (also as a model for the liver-specific 
consequences of activating drugs on GK) could increase glucose uptake compared with the 
wild-type enzyme at equal levels of expression, whilst the metabolic fate of glucose might be 
different from that of wild-type GK due to its different capacity of interaction with other 
regulating proteins (GKRP and maybe PFK-2). 
By means of hydrodynamic gene transfer of an expression plasmid for GK-A456V in healthy 
mice, we have been able to demonstrate that the perivenous overexpression of GK-A456V 
results in a sustained improvement in blood glucose, insulinemia and glucose tolerance, in 
the absence of dyslipidemia or hepatic lipidosis nor long-term insulin resistance (Vidal-
Alabró; publication pending). Importantly, GK-A456V protein levels were similar to GK-
control group, suggesting GK-A456V stability although not being directly regulated by 
GKRP. Its mechanism of action could be explained by its lower S0.5 for glucose, so that 
glucose uptake is stimulated in later phases after ingestion (post absorptive phase) and 
during early fasting. It is tempting to speculate that glucose taken-up in perivenous liver, 
both in postprandial and post-absorptive periods, could be directed towards the glycolytic 
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and oxidative metabolism and not through the pentose phosphate pathway that would favor 
lipid biosynthesis. This hypothesis is reinforced by results published by Wu et al (Wu, 2005) in 
which adenovirus expression of wild-type GK in the liver activate the pentose phosphate 
pathway, in marked contrast to the overexpression of the kinase domain from PFK-2 that 
stimulates flux through the glycolytic pathway. Surprisingly, GK-A456V transfected animals 
showed a marked increase in glucose-6-phosphatase. GK overexpression in perivenous 
hepatocytes does not significantly affect Glc6Pase expression, suggesting that zonation is an 
important experimental variable not sufficiently addressed to date in the field. 
Transfecting GK-A456V in type 1 diabetic mice induced with streptozotocin, also caused an 
important reduction of diabetic hyperglycemia without dyslipidemia, in contrast with GK 
overexpression. Again, an induction of glucose-6-phosphatase transcription was observed in 
the liver GK-A456V -expressing animals (Figure 7) (Vidal-Alabró; publication pending).  
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Fig. 7. Study of GK-A456V expression in the liver of type 1 diabetic mice. (A) Shows 
glycaemia, serum triglyceride and free fatty acid levels, 48 h post-injection of the plasmid for 
the GK-A456V gene. Columns represent media ± standard error. (B) Expression of 
gluconeogenic and lipolysis genes from liver was analyzed by Real-Time PCR. Calculations 
were done following ΔΔCt algorithm (Applied Biosystems), using ǃ-microglobulin gene 
expression as a housekeeping gene. (C) The same for lipogenic genes. * p<0.05, # p<0.05 vs 
control and pGK, and & p<0.001 vs control and p<0.05 vs pGK-A456V, as determined by 
One-way ANOVA.  
Our results lead us to consider the physiology of glucose-6-phosphatase in the context of 
glucose and lipid metabolism. Glucose-6-phosphatase dephosphorylates glucose-6-
phosphate in the endoplasmic reticulum to obtain glucose, as the last step in the 
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gluconeogenic pathway. Its transcription is regulated by insulin, so that it is repressed in 
fed state and induced during fasting. However, glucose induces transcription of this 
enzyme although the physiological significance of this induction is still not resolved 
(Nordlie, 2010). Finally glucose-6-phosphatase deficiency causes severe hyperlipidemia 
and hepatic steatosis (Bandsma, 2002, 2008), therefore giving rise that this enzyme may 
also participate or influence the GK/GKRP system in the regulation of hepatic glucose 
fate. To support this hypothesis, Reiling and colleagues described combined effects of 
single-nucleotide polymorphisms in GK, GKRP and glucose-6-phosphatase on fasting 
plasma glucose and type 2 diabetes (Reiling, 2009). Therefore, it is a field that needs 
further exploration.  
5. Conclusion 
Subtle changes in GK activity or in GKRP function have consequences in glucose and lipid 
metabolism. However, further studies must be done to completely understand the 
mechanism underlying GK/GKRP biology. Our results on increasing GK protein in the liver 
of both healthy and insulin-deficient mice (lacking endogenous GK) resulted in 
dyslipidemia. On the other hand, our analysis of the metabolic consequences of GK-GKRP 
deregulation by overexpressing a GK activating mutant (GKA456V) in the liver of both 
healthy and type 1 diabetic mice demonstrates an impact on glycaemia in the absence of 
dyslipidemia or hepatic lipid deposition. These data provide novel insights into the capacity 
of the complex GK-GKRP to influence the fate of metabolized glucose in the liver, providing 
a framework for further research on GK activating drugs in the liver. 
We conclude that GKRP regulation impairment and GK-A456V altered kinetics greatly 
influence liver metabolism, in line with results in humans carrying a mutant GKRP (Køster, 
2005; Sparsø, 2007; Vaxillaire, 2008 & Orho-Melander, 2008). Besides, it suggests that 
activating GK exclusively in the liver could be a feasible strategy to funnel excess glucose 
from the diet out of circulation, widening the scope for GK synthetic activators research.  
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